Welcome to our dedicated page for Alumis news (Ticker: ALMS), a resource for investors and traders seeking the latest updates and insights on Alumis stock.
Alumis Inc (ALMS) is a clinical-stage biopharmaceutical company advancing precision oral therapies for immune-mediated diseases through its proprietary data analytics platform. This page provides investors and industry stakeholders with centralized access to validated updates on the company’s clinical programs, regulatory milestones, and scientific advancements.
Track developments across Alumis’ pipeline including ESK-001, a selective TYK2 inhibitor in Phase 3 trials for plaque psoriasis and lupus, and A-005, a CNS-penetrant candidate targeting neuroinflammatory conditions. Our news collection covers essential updates such as clinical trial results, partnership announcements, and regulatory submissions while maintaining compliance with financial disclosure standards.
Key content categories include trial progression updates, peer-reviewed data publications, executive leadership changes, and strategic collaborations. All materials are curated to provide actionable insights without speculative commentary or investment recommendations.
Bookmark this page for streamlined access to Alumis’ latest developments in transforming autoimmune disease treatment through precision-targeted therapies. Verify information through primary sources via linked press releases and official filings where available.
Alumis (NASDAQ: ALMS) and ACELYRIN have announced an amended merger agreement with revised ownership terms. Under the new agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share, resulting in Alumis stockholders owning approximately 52% and ACELYRIN stockholders owning 48% of the combined company.
The merger aims to create a leading clinical-stage immunology company with enhanced financial flexibility. The combined entity will have a pro forma cash position of approximately $737 million as of December 31, 2024, with funding expected to last into 2027. The transaction has received unanimous approval from both companies' boards, with stockholder voting agreements already secured from 62% of Alumis and 24% of ACELYRIN shareholders.
Special stockholder meetings are scheduled for May 13, 2025, with the transaction expected to close in Q2 2025, subject to stockholder approval and customary closing conditions.
Alumis (NASDAQ: ALMS) and ACELYRIN have filed a definitive proxy statement for their proposed merger, scheduled for completion in Q2 2025. The merger will create a late-stage clinical biopharma company focused on immune-mediated diseases with a pro forma cash position of $737 million, providing runway into 2027.
Key pipeline milestones include Phase 3 ONWARD trials for ESK-001 in psoriasis (1Q 2026), Phase 2b LUMUS trial in lupus (2026), Phase 2 trial initiation for A-005 in MS, and development of lonigutamab for thyroid eye disease.
Under the agreement, ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock per share, resulting in Alumis stockholders owning 55% and ACELYRIN stockholders owning 45% of the combined company. Special stockholder meetings will be held virtually on May 13, 2025, with a record date of April 1, 2025.
Alumis (NASDAQ: ALMS) and Kaken Pharmaceutical have announced a collaboration and licensing agreement for ESK-001, a next-generation oral TYK2 inhibitor, in Japan. The deal includes $40 million in upfront and near-term co-development payments during 2025-2026, with potential for additional $140 million in milestone and field option payments, plus tiered royalties ranging from low double-digits to twenties on net sales.
Kaken will handle clinical development, regulatory approvals, and commercialization of ESK-001 in Japan for dermatology indications, with an option to expand into rheumatological and gastrointestinal diseases. The company will also contribute to global development costs, while Alumis retains rights in all other regions. The partnership builds on ESK-001's positive Phase 2 clinical data.
Alumis (NASDAQ: ALMS) reported its 2024 financial results and key milestones. The company presented promising 52-week Phase 2 STRIDE OLE data for ESK-001, their next-generation oral TYK2 inhibitor for psoriasis, with Phase 3 ONWARD program results expected in Q1 2026. They also shared positive Phase 1 data for A-005, their CNS-penetrant TYK2 inhibitor, with Phase 2 MS trials starting in H2 2025.
A significant merger with ACELYRIN was announced, expected to close in Q2 2025, creating a combined entity with Alumis stockholders owning 55%. The merged company will have approximately $737 million in cash (as of December 31, 2024), extending runway into 2027.
Financial highlights for 2024 include:
- Cash position: $288.3 million
- R&D expenses: $265.6 million (up from $137.7 million in 2023)
- G&A expenses: $35.2 million (up from $20.5 million in 2023)
- Net loss: $294.2 million (compared to $155.0 million in 2023)
Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company focused on developing oral precision therapies for immune-mediated diseases, has announced its participation in Leerink's 2025 Global Healthcare Conference.
Company President and CEO Martin Babler will engage in a fireside chat scheduled for Tuesday, March 11, 2025, at 10:40 am ET. Interested parties can access a live webcast of the presentation through the 'Events' page in the 'Investors' section of the Alumis website.
Alumis (NASDAQ: ALMS) has presented positive 52-week data from the open-label extension (OLE) of its Phase 2 STRIDE clinical trial for ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis. The data was showcased at the 2025 AAD Annual Meeting.
The trial results showed patients receiving 40 mg twice daily achieved sustained or increasing clinical responses through Week 52 compared to Week 12, with:
- PASI 90: 61.3% vs. 52.4%
- PASI 100: 38.8% vs. 26.8%
- sPGA 0: 38.8% vs. 32.9%
At Week 52, patients maintained robust improvements in itch control (NRS≤4, 81.3%) and quality-of-life (DLQI0/1, 61.3%). The treatment was generally well-tolerated with no new safety concerns. The company expects topline data from the Phase 3 ONWARD program in Q1 2026.
Alumis (NASDAQ: ALMS) and ACELYRIN (NASDAQ: SLRN) have reaffirmed their commitment to merge in an all-stock transaction, creating a leading clinical-stage biopharma company focused on immune-mediated diseases. The merger is expected to close in Q2 2025.
The combined entity will have a pro forma cash position of approximately $737 million as of December 31, 2024, providing runway into 2027. The portfolio includes late-stage clinical assets targeting multi-billion dollar markets, including ESK-001 for psoriasis and lupus, lonigutamab for thyroid eye disease, and A-005 for multiple sclerosis.
Key benefits include:
- Enhanced financial flexibility to advance late-stage pipeline
- Combined cash position from Alumis ($289M) and ACELYRIN ($448M)
- Multiple planned key data readouts across clinical trials
- Experienced leadership team with track record of value creation
Alumis (NASDAQ: ALMS) has announced multiple presentations of its Phase 2 open-label extension (OLE) study data for ESK-001, their oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, at the 2025 American Academy of Dermatology (AAD) annual meeting in Orlando.
The presentations include a late-breaking oral presentation highlighting 52-week data and three e-posters covering patient-reported outcomes, disease biomarker activity, and pharmacokinetic data. The company will present findings on March 8, 2025, with additional e-poster presentations focusing on Asian population comparisons and biomarker modulation.
Notably, Alumis has accelerated its timeline for the Phase 3 ONWARD clinical program topline data readout, now expected in Q1 2026, citing strong patient and investigator interest in the program.
Alumis (Nasdaq: ALMS) announced new Phase 1 data presentations for A-005, their first-in-class CNS penetrant TYK2 inhibitor, at the ACTRIMS Forum 2025. A-005 demonstrated potent inhibition of TYK2-specific signaling in immune cells and CNS resident cells, with the ability to cross the blood-brain barrier.
The Phase 1 clinical trials showed that A-005 was well-tolerated and achieved maximal TYK2 inhibition across various doses. The company plans to advance to Phase 2 clinical trials for multiple sclerosis patients in the second half of 2025.
Two presentations are scheduled for February 28, 2025: one focusing on A-005's effects on astrocytes and microglia (Poster P352), and another discussing safety, tolerability, and pharmacokinetics in healthy volunteers (Poster P335).
Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Martin Babler, the company's President and CEO, will deliver a presentation at the virtual event on Tuesday, February 11, 2025, at 3:20 pm ET. Interested parties can access a live webcast of the presentation through the 'Events' page in the 'Investors' section of the Alumis website.
